SynthesisExpert opinion on drug safety2021
Tafenoquine: a toxicity overview.
Synthesis in Expert opinion on drug safety, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Systematic review and individual patient data meta-analysis on glucose- 6 - phosphate dehydrogenase activities measured by a semi-quantitative handheld biosensor.Malaria journal · 2025Pooled it
- Effect of Stereochemistry on the Antiplasmodial Activity and Metabolomic Profile of Novel Tadalafil Analogues.ACS medicinal chemistry letters · 2026Article
- Potent acridone antimalarial against all three life stages of Plasmodium.Nature communications · 2026Article
- Physiologically based pharmacokinetic modeling of tafenoquine and evaluation of transporter-mediated drug-drug interactions.Frontiers in pharmacology · 2026Article
- Tafenoquine lactation pharmacokinetics: a pilot study.Malaria journal · 2025Article
- CUREMA project: a further step towards malaria elimination among hard-to-reach and mobile populations.Malaria journal · 2024Article
- Novel Antibacterial Agents 2022.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis.PLoS neglected tropical diseases · 2023Article
- Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency.PLoS neglected tropical diseases · 2023Observational
- Plasma Blood Levels of Tafenoquine following a Single Oral Dosage in BALBc Mice with AcutePathogens (Basel, Switzerland) · 2023Article
- Comparative pharmacokinetics and tissue distribution of primaquine enantiomers in mice.Malaria journal · 2022Article
- Study of Tissue-Specific Reactive Oxygen Species Formation by Cell Membrane Microarrays for the Characterization of Bioactive Compounds.Membranes · 2021Article
- Treatment of Human Babesiosis: Then and Now.Pathogens (Basel, Switzerland) · 2021Review
- SERCAP: is the perfect the enemy of the good?Malaria journal · 2021Article
- Taking on Plasmodium vivax malaria: A timely and important challenge.PLoS medicine · 2021Article
- Genetic Variation ofFrontiers in pharmacology · 2021Article
- Safety and Efficacy of Tafenoquine forTherapeutics and clinical risk management · 2021Article
- An update on prevention of malaria in travelers.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.